NKGen Biotech secures $552K convertible loan from AlpineBrook Capital
What's the deal? NKGen Biotech, a small-cap biotech focused on natural killer cell therapies, has amended its secured convertible loan agreement with AlpineBrook Capital to raise an additional $607,200 in convertible debt — yielding $552,000 in net proceeds. The deal, signed on April 28, includes a conversion price of $0.08 per share, a new 10-year warrant with a 9.99% ownership cap, and anti-dilution protections for the lender.
As part of the arrangement, NKGen increased consideration shares to 12,009,780 and entered a voting agreement with key shareholders to support raising the company's authorised common share count — a necessary step to accommodate potential conversions and warrant exercises.
The company has a current market cap of roughly $7.84M and average daily trading volume of just 5,100 shares.
Why now? NKGen operates through convertible debt and equity-linked securities to fund its operations, a common pattern for pre-revenue biotech firms that lack cash flow. The amended deal deepens AlpineBrook's economic exposure and suggests the company needs continued capital infusions to keep its NK cell therapy programmes moving forward.
What could go wrong? The structure raises clear dilution risks for existing shareholders. A conversion price of $0.08 per share, combined with a 10-year warrant and expanded share authorisation, could significantly increase the total share count over time.
The voting agreement — which commits key shareholders to backing an increase in authorised shares — signals that NKGen's capital structure may shift further toward equity dilution as subsequent financings close. For a company with a sub-$10M market cap and thin trading volume, that's a material concern.
The signal: NKGen's continued reliance on deeply discounted convertible debt underscores the funding squeeze facing micro-cap biotechs with limited public market liquidity. With a sub-$10M market cap and average daily volume of just 5,100 shares, the company has few options beyond lender-friendly structures that trade governance concessions and dilution risk for near-term survival capital — a pattern increasingly common among pre-revenue cell therapy firms struggling to attract institutional backing.
Read more: blog.tipranks.com
